Accuray (NASDAQ:ARAY) Issues Quarterly Earnings Results

Accuray (NASDAQ:ARAY) released its quarterly earnings data on Wednesday. The medical equipment provider reported $0.03 earnings per share for the quarter, hitting the consensus estimate of $0.03, RTT News reports. The business had revenue of $134.29 million during the quarter, compared to analyst estimates of $122.80 million. Accuray had a negative return on equity of 44.46% and a negative net margin of 4.99%. During the same period last year, the company posted ($0.03) EPS. Accuray updated its FY 2025 guidance to EPS.

Accuray Stock Up 40.9 %

Shares of ARAY traded up $0.58 during mid-day trading on Thursday, reaching $2.01. The company’s stock had a trading volume of 12,724,423 shares, compared to its average volume of 632,696. The company has a market cap of $199.90 million, a price-to-earnings ratio of -9.14 and a beta of 1.45. The business has a fifty day moving average of $1.76 and a 200 day moving average of $2.09. The company has a quick ratio of 0.78, a current ratio of 1.58 and a debt-to-equity ratio of 4.05. Accuray has a 1 year low of $1.40 and a 1 year high of $3.10.

Insider Activity at Accuray

In other Accuray news, Director Joseph E. Whitters bought 50,000 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were bought at an average price of $1.54 per share, for a total transaction of $77,000.00. Following the acquisition, the director now directly owns 511,053 shares of the company’s stock, valued at $787,021.62. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.78% of the stock is owned by insiders.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.